

Contents

<i>Contents of Volume I</i>	ix
<i>Contents of Volume II</i>	xiii
<i>About the Primary Authors</i>	xvii
<i>Guest Contributors</i>	xix
<i>Acknowledgments</i>	xxi
<i>Disclosures</i>	xxiii
<i>From the Series Editor</i>	xxv
<i>Authors' Preface to Volume III</i>	xxvii
15 INDUSTRIAL AND ENVIRONMENTAL AGENTS	735
Selected presentations 737	
<i>Carbon monoxide poisoning</i> 737	
<i>Lead in adults</i> 746	
<i>Lead in children</i> 754	
<i>Organic mercury</i> 778	
<i>Pesticides</i> 790	
<i>Solvents</i> 801	
Summary 815	
16 MEDICATIONS AND SUBSTANCES OF ABUSE	835
Selected presentations 835	
<i>Anticonvulsants</i> 835	
<i>Amphetamines</i> 846	
<i>Clioquinol</i> 857	
<i>Corticosteroids</i> 879	
<i>Cyclosporine</i> 893	
<i>Ethyl alcohol</i> 902	
<i>Hypnotics and sedatives</i> 923	
<i>Lithium</i> 932	
<i>Pain medications (opioids)</i> 941	

Psychotropic medications (chlorpromazine) 952
Toluene 960
Summary 970

17 CONDITIONS ASSOCIATED WITH OR SOMETIMES MIMIC TOXIC-INDUCED CENTRAL NERVOUS SYSTEM DISEASE

999

The influence of aging on clinical and psychometric examinations 999
Issues of accommodation in evaluating the elderly 1002
Issues of bias 1004
Normative data in the context of age 1005
Models of cognitive change in aging 1010
Conclusion 1013
Psychological and emotional considerations in central nervous system disease 1014
Case presentation 1014
Discussion 1015
The importance of understanding normal behavior 1016
When is behavior abnormal? 1017
Models of abnormality 1018
The formal diagnosis of psychopathology 1019
Anxiety 1020
Mood disorders 1032
Somatoform disorder 1039
Other psychological/psychiatric considerations 1055
Neurological or medical conditions associated with or mimicking toxic-induced central nervous system disease 1066
Dementia 1066
Headache 1081
Hepatic encephalopathy 1093
Hypothyroidism 1100
Hypoxic encephalopathy 1112
Parkinson's disease and parkinsonism 1129
Summary 1145

18 CONSEQUENCES OF AN INCOMPLETE DIFFERENTIAL DIAGNOSIS

1171

Selected presentations 1171
Child with behavioral and learning problems attributed to ethylmercury 1171
Depression in a chronic medical condition 1187
Neurobehavioral complaints attributed to mold exposure 1192

<i>Patient with neurobehavioral symptoms attributed to dental amalgams</i>	1208
<i>Patient with history of head injury</i>	1224
<i>Patient with neuropsychological complaints attributed to diet drugs</i>	1234
<i>Patient with presumed arsenic-induced neurotoxicity</i>	1242
<i>Solvent-exposed mechanic with dementia</i>	1252
<i>Solvent-exposed machinist with behavioral and neurological complaints</i>	1263
Summary	1282

19 ISSUES AND CONTROVERSIES INVOLVING THE CENTRAL NERVOUS SYSTEM EVALUATION	1311
The complexity of the neurobehavioral examination	1311
Patient with toxic exposure and multiple explanations for his complaints	1311
Factors influencing the evaluation	1319
<i>Individual differences</i>	1319
<i>Other considerations that influence or even explain the patient's complaints and examination findings</i>	1320
Approaching the differential diagnosis from a neurobehavioral perspective	1332
<i>The role of neuropsychological testing in the examination</i>	1333
<i>The importance of ancillary test results</i>	1335
<i>The importance of the patient history and interview</i>	1336
Establishing causation in clinical neurotoxicological investigations	1337
Controversial neurotoxic disorders involving the central nervous system	1339
Summary	1347
 APPENDIX	 1353
<i>Index</i>	1355